On March 9, 2022, Apeloa Pharmaceutical Co.Ltd(000739) ( Apeloa Pharmaceutical Co.Ltd(000739) . SZ) released the annual report for 2021: the company achieved an annual operating revenue of 8.943 billion yuan, a year-on-year increase of 13.49%; The net profit attributable to the parent company was 956 million yuan, a year-on-year increase of 17.00%; The net profit attributable to the parent company after deduction was 833 million yuan, with a year-on-year increase of 20.53%.
In terms of revenue structure, Apeloa Pharmaceutical Co.Ltd(000739) business is mainly divided into API, cdmo and FDF, accounting for 73.20%, 15.59% and 9.70% of total revenue respectively.
Apeloa Pharmaceutical Co.Ltd(000739) takes "refining API, strengthening cdmo and making excellent preparation" as the long-term development strategy, and the positioning of these three business segments is also clarified in this strategic plan.
